Gilead Sciences (English Wikipedia)

Moukheiber, Kerry A. Dolan Zina. "The Golden Age of Antiviral Drugs". Forbes. Retrieved December 14, 2017.
Moukheiber, Zina; Dolan, Kerry A. (October 27, 2003). "The Golden Age of Antiviral Drugs". Forbes.
"Grading Pharma in 2013". Forbes. December 31, 2013.

fortune.com

"The Giving 20: The Most Generous Companies in America". Fortune. Retrieved December 14, 2017.

ft.com

Kazmin, Amy (April 12, 2015). "Pharma combats diversion of cheap drugs". Financial Times. Retrieved September 27, 2021.

fundinguniverse.com

"History of Gilead Sciences, Inc. – FundingUniverse". fundinguniverse.com.

genengnews.com

Staff, G. E. N. (July 25, 2006). "Gilead Buys Corus Pharma for $365 million". GEN - Genetic Engineering and Biotechnology News. Retrieved September 27, 2024.
"Gilead to Acquire Phenex's FXR Program for Up-to-$470M". Genetic Engineering and Biotechnology News: GEN.
"Gilead Boosts Cancer Pipeline With $65M EpiTherapeutics Buy". Genetic Engineering and Biotechnology News: GEN. May 6, 2015.

gilead.com

"U.S. Food And Drug Administration (FDA) Approves Atripla" (Press release). Gilead Sciences and Bristol-Myers Squibb. July 12, 2006. Archived from the original on November 15, 2008. Retrieved December 15, 2007.
"Gilead Sciences Completes Acquisition of Raylo Chemicals Inc" (Press release). Gilead Sciences. November 3, 2006. Archived from the original on January 16, 2013. Retrieved June 7, 2007.
"Parion Sciences and Gilead Sciences Sign Agreement to Advance Drug Candidates for Pulmonary Disease" (Press release). Gilead Sciences. August 15, 2007. Archived from the original on February 8, 2013. Retrieved August 15, 2007.
"Gilead Sciences to Acquire Arresto Biosciences for $225 Million; Deal Adds Pipeline Candidates for Fibrotic Diseases" (Press release). Gilead Sciences. December 20, 2010. Archived from the original on January 13, 2011. Retrieved January 15, 2011.
"Gilead Sciences to Acquire Calistoga Pharmaceuticals for $375 Million". Gilead Sciences, Inc. (Press release). February 22, 2011. Retrieved July 12, 2020.
"Gilead Sciences to Acquire Immunomedics".
"Gilead Statement on Zydelig® U.S. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia". www.gilead.com. Retrieved February 7, 2022.
"Mission & Core Values – Gilead". www.gilead.com. Archived from the original on August 11, 2022. Retrieved March 27, 2019.

investors.gilead.com

"Gilead Sciences to Acquire Calistoga Pharmaceuticals for $375 Million; Deal Adds Pipeline Candidates in Oncology and Inflammation" (Press release). Gilead Sciences. February 22, 2011. Archived from the original on July 9, 2012. Retrieved February 22, 2011.
"Gilead Sciences Announces Acquisition of Nimbus Therapeutics' Acetyl-CoA Carboxylase (ACC) Program for NASH and Other Liver Diseases | Gilead Sciences". investors.gilead.com. Archived from the original on September 23, 2021. Retrieved September 23, 2021.
"Gilead Completes Acquisition of Forty Seven, Inc". Gilead Sciences. Archived from the original on April 25, 2022. Retrieved April 11, 2020.
"Gilead Sciences, Inc. 2019 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. Gilead Sciences. February 2020. Archived from the original (PDF) on March 13, 2022. Retrieved April 19, 2020.

healio.com

"FDA approves first generic of Tamiflu for influenza A, B". www.healio.com. August 4, 2016. Retrieved April 3, 2020.

independent.co.uk

"Donald Rumsfeld makes $5m killing on bird flu drug". The Independent. March 12, 2006. Retrieved August 2, 2020.

investors.com

Allison Gatlin (April 6, 2017). "Will Gilead's HIV Franchise Plan Be Dashed On TrumpCare?". Investor's Business Daily. Investors Business Daily.

jennerlawfirm.com

Jenner, Rob (January 12, 2024). ""Morally Blameworthy" Gilead Under Fire in Legal Battle Over HIV Medication". Jenner Law, Baltimore MD. Retrieved January 12, 2024.

ktvq.com

"Donald Rumsfeld Fast Facts". KTVQ. June 27, 2019. Retrieved April 3, 2020.

latimes.com

Gellene, Denise (December 5, 2002). "Gilead Sciences to Buy Triangle Pharmaceuticals". Los Angeles Times.
Petersen, Melody (May 5, 2018). "Patients sue Gilead, saying drug company intentionally delayed safer HIV medicine". Los Angeles Times. Retrieved December 7, 2019.
Petersen, Melody (May 9, 2018). "Patients sue Gilead, saying drug company intentionally delayed safer HIV medicine". Los Angeles Times. Retrieved March 11, 2022.

lexpert.ca

"Gilead Sciences Acquires YM Biosciences". www.lexpert.ca. Retrieved October 23, 2024.

macrotrends.net

"Gilead Sciences Revenue 2006–2018". www.macrotrends.net. Retrieved November 1, 2018.

msf.org

"No profiteering on COVID-19 drugs and vaccines, says MSF". Médecins Sans Frontières (MSF) International.

msn.com

today.msnbc.msn.com

Perrone, Matthew. "FDA approves first pill to help prevent HIV". Today Health. NBC News. Archived from the original on July 16, 2012. Retrieved July 16, 2012.

nbcnews.com

Fitzsimmons, Tim (July 19, 2018). "#BreakThePatent: How HIV activists are going after Gilead's PrEP patent". NBC News. Retrieved September 19, 2021.
Ryan, Benjamin (July 7, 2021). "Pharma giant's policy change will devastate local HIV-prevention clinics' efforts". NBC News. Retrieved September 23, 2021.

nih.gov

pubmed.ncbi.nlm.nih.gov

Masho, Saba Woldemichael; Wang, Cun-Lin; Nixon, Daniel E (December 2007). "Review of tenofovir-emtricitabine". Therapeutics and Clinical Risk Management. 3 (6): 1097–1104. ISSN 1176-6336. PMC 2387297. PMID 18516268.
Keating GM (2015). "Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C". Drugs. 75 (6): 675–85. doi:10.1007/s40265-015-0381-2. PMID 25837989. S2CID 31943736.
Tourret, Jérôme; Deray, Gilbert; Isnard-Bagnis, Corinne (2013). "Tenofovir Effect on the Kidneys of HIV-Infected Patients: A Double-Edged Sword?". Journal of the American Society of Nephrology. 24 (10): 1519–1527. doi:10.1681/ASN.2012080857. PMC 3785270. PMID 24052632.
Grigsby, Iwen F.; Pham, Lan; Mansky, Louis M.; Gopalakrishnan, Raj; Mansky, Kim C. (2010). "Tenofovir-associated bone density loss". Therapeutics and Clinical Risk Management. 6: 41–47. PMC 2817787. PMID 20169035.
Walensky, Rochelle P.; Horn, Tim; McCann, Nicole C.; Freedberg, Kenneth A.; Paltiel, A. David (May 5, 2020). "Comparative Pricing of Branded Tenofovir Alafenamide–Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate–Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis". Annals of Internal Medicine. 172 (9): 583–590. doi:10.7326/m19-3478. PMC 7217721. PMID 32150602.
Rizk, John G.; Forthal, Donald N.; Kalantar-Zadeh, Kamyar; Mehra, Mandeep R.; Lavie, Carl J.; Rizk, Youssef; Pfeiffer, JoAnn P.; Lewin, John C. (2021). "Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic". Drug Discovery Today. 26 (2): 593–603. doi:10.1016/j.drudis.2020.11.025. ISSN 1359-6446. PMC 7694556. PMID 33253920.
Lamontagne F, Agoritsas T, Macdonald H, Leo YS, et al. (September 2020). "A living WHO guideline on drugs for covid-19". BMJ. 370: m3379. doi:10.1136/bmj.m3379. PMID 32887691. S2CID 221498813.
Ali K, Azher T, Baqi M, Binnie A, et al. (January 2022). "Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial". Canadian Medical Association Journal. 194 (7): E242–E251. doi:10.1503/cmaj.211698. PMC 8863204. PMID 35045989.

ncbi.nlm.nih.gov

Masho, Saba Woldemichael; Wang, Cun-Lin; Nixon, Daniel E (December 2007). "Review of tenofovir-emtricitabine". Therapeutics and Clinical Risk Management. 3 (6): 1097–1104. ISSN 1176-6336. PMC 2387297. PMID 18516268.
Tourret, Jérôme; Deray, Gilbert; Isnard-Bagnis, Corinne (2013). "Tenofovir Effect on the Kidneys of HIV-Infected Patients: A Double-Edged Sword?". Journal of the American Society of Nephrology. 24 (10): 1519–1527. doi:10.1681/ASN.2012080857. PMC 3785270. PMID 24052632.
Grigsby, Iwen F.; Pham, Lan; Mansky, Louis M.; Gopalakrishnan, Raj; Mansky, Kim C. (2010). "Tenofovir-associated bone density loss". Therapeutics and Clinical Risk Management. 6: 41–47. PMC 2817787. PMID 20169035.
Walensky, Rochelle P.; Horn, Tim; McCann, Nicole C.; Freedberg, Kenneth A.; Paltiel, A. David (May 5, 2020). "Comparative Pricing of Branded Tenofovir Alafenamide–Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate–Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis". Annals of Internal Medicine. 172 (9): 583–590. doi:10.7326/m19-3478. PMC 7217721. PMID 32150602.
Rizk, John G.; Forthal, Donald N.; Kalantar-Zadeh, Kamyar; Mehra, Mandeep R.; Lavie, Carl J.; Rizk, Youssef; Pfeiffer, JoAnn P.; Lewin, John C. (2021). "Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic". Drug Discovery Today. 26 (2): 593–603. doi:10.1016/j.drudis.2020.11.025. ISSN 1359-6446. PMC 7694556. PMID 33253920.
Ali K, Azher T, Baqi M, Binnie A, et al. (January 2022). "Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial". Canadian Medical Association Journal. 194 (7): E242–E251. doi:10.1503/cmaj.211698. PMC 8863204. PMID 35045989.

nih.gov

"Harold E. Varmus, M.D." National Institutes of Health (NIH). August 6, 2015. Retrieved February 25, 2019.

aidsinfo.nih.gov

"FDA approves first drug for reducing the risk of sexually acquired HIV infection" (Press release). July 16, 2012. Retrieved July 12, 2020.

npr.org

Simmons-Duffin, Selena (May 30, 2019). "AIDS Activists Take Aim At Gilead To Lower Price Of HIV Drug PrEP". NPR. Retrieved September 19, 2021.
Lupkin, Sydney (March 24, 2020). "FDA Grants Experimental Coronavirus Drug Benefits For Rare Disease Treatments". NPR. Retrieved March 24, 2020.

nytimes.com

Fisher, Lawrence M. (June 28, 1996). "F.D.A. Approves Gilead's Drug for AIDS Patients". The New York Times. ISSN 0362-4331. Retrieved September 22, 2021.
McFadden, Robert D. (June 30, 2021). "Donald H. Rumsfeld, Defense Secretary During Iraq War, Is Dead at 88". The New York Times. Retrieved October 23, 2024.
Pollack, Andrew (July 13, 2006). "F.D.A. Backs AIDS Pill to Be Taken Once a Day". The New York Times. Retrieved September 20, 2007.
"Gilead to Buy CV Therapeutics for $1.4 Billion". The New York Times. Reuters. March 12, 2009. Retrieved April 25, 2020.
McNeil, Jr., Donald G. (May 9, 2019). "Gilead Will Donate Truvada to U.S. for H.I.V. Prevention". The New York Times. ISSN 0362-4331. Retrieved December 4, 2019.
McNeil, Jr., Donald G. (December 3, 2019). "200,000 Uninsured Americans to Get Free H.I.V.-Prevention Drugs". The New York Times. ISSN 0362-4331. Retrieved December 4, 2019.
Sanger-Katz, Margot (August 2, 2014). "Critics Raise Concerns About Sovaldi". The New York Times. ISSN 0362-4331. Retrieved October 4, 2015.
McNeil, Donald G. (May 10, 2019). "Gilead Will Donate Truvada to U.S. for H.I.V. Prevention". The New York Times. Retrieved September 20, 2021.

outsourcing-pharma.com

Stanton, Dan (May 20, 2015). "Gilead's reliance on CMOs gives firm 'flexibility' says CFO". Outsourcing-Pharma.com. Crawley: William Reed Business Media Ltd. Retrieved April 1, 2020.

parentherald.com

"Gilead Sciences: Nimbus Drug Acquired, Offering Cure For Fatty Liver". Parent Herald. April 6, 2016.

pharmaceutical-technology.com

Priyan, Vishnu (September 11, 2024). "Gilead and Genesis partner to create novel therapies using AI". Pharmaceutical Technology. Retrieved September 16, 2024.

pharmatimes.com

"Roche settles dispute with Gilead over Tamiflu". PharmaTimes. November 17, 2005. Retrieved September 19, 2021.

policymed.com

Sullivan, Thomas (May 5, 2018). "Senate Finance Committee Releases Results of Investigation Into Gilead's Pricing Strategy for Hepatitis-C Drugs". Policy & Medicine.

reuters.com

"Gilead to buy Kite for promising cancer therapies in $12 billion deal". reuters.com. August 28, 2017.
"Gilead to buy Cell Design Labs for up to $567 million". reuters.com. December 7, 2017. Archived from the original on June 6, 2020.
"Gilead buys Forty Seven for $4.9 billion to bolster cancer drug pipeline". Reuters. March 2, 2020. Archived from the original on March 27, 2022.
"Gilead to buy 49.9% stake in cancer drug developer for $275 million". Reuters. June 23, 2020 – via www.reuters.com.
"Gilead to acquire German biotech firm MYR for about 1.15 billion euros". Reuters. December 10, 2020 – via www.reuters.com.
Beasley, Deena (May 6, 2020). "Will Gilead price its coronavirus drug for public good or company profit?". Reuters. Retrieved September 19, 2021. Public outrage over the cost of Sovaldi in 2013 - despite that it was a vast improvement over existing equally expensive therapies - ignited a national debate on fair pricing for prescription medicines that the pharmaceutical industry has fought to deflect ever since.
Rapaport, Lisa (March 9, 2020). "New brand-name HIV-prevention pill not worth the added cost: study". Reuters. Retrieved September 23, 2021.

scribd.com

"Gilead Sciences Board Resolution Michael Riordan Founder CEO Chairman Antiviral Medicine AIDS Therapeutics Nucleotides". Scribd. Retrieved December 14, 2017.

sec.gov

"Gilead Sciences, Inc. 2023 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. February 23, 2024.
"Gilead Sciences, Inc. 2021 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. Gilead Sciences. February 23, 2022.

seekingalpha.com

"Gilead Q4 2014 Earnings Call". February 3, 2015.
Ioannis Stamatopoulos (February 12, 2017). "Pharma M&A In 2017: The Most Likely Deal Hunters". Seeking Alpha. Retrieved March 12, 2017.
Dulan Lokuwithana (October 28, 2021). "Gilead lifts 2021 guidance as remdesivir sales more than double in Q3". Seeking Alpha. Retrieved January 25, 2022.

semanticscholar.org

api.semanticscholar.org

Keating GM (2015). "Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C". Drugs. 75 (6): 675–85. doi:10.1007/s40265-015-0381-2. PMID 25837989. S2CID 31943736.
Lamontagne F, Agoritsas T, Macdonald H, Leo YS, et al. (September 2020). "A living WHO guideline on drugs for covid-19". BMJ. 370: m3379. doi:10.1136/bmj.m3379. PMID 32887691. S2CID 221498813.

sfgate.com

Tansey, Bernadette (April 14, 2003). "Profile: Gilead Sciences / Gilead grows up / Visionary biotech startup matures into pragmatic industry leader". San Francisco Chronicle. Hearst Communications, Inc. p. E1. Retrieved March 21, 2020.

smh.com.au

Hammond, Ed; Kirchfeld, Aaron; Nair, Dinesh (June 7, 2020). "A new pharma king? AstraZeneca approaches Gilead about potential merger: report". The Sydney Morning Herald. Retrieved June 8, 2020.

statnews.com

Silverman, Ed (July 13, 2016). "Gilead avoided nearly $10 billion in taxes last year thanks to tax dodges". Stat News. Retrieved January 2, 2022.

streetinsider.com

"Q4 Sovaldi Sales Tracking at $53 Million". Street Insider. January 3, 2014.

thepharmaletter.com

"Veklury becomes first option for COVID-19 approved in EU". The Pharma Letter. March 7, 2020. Retrieved January 25, 2022.

thetimes.co.uk

Paul O'Donoghue (December 26, 2018). "US pharma giant Gilead uses 'Double Irish' tax loophole". The Times. London.

washingtonpost.com

Rowland, Christopher (March 26, 2019). "An HIV treatment cost taxpayers millions. The government patented it. But a pharma giant is making billions". Washington Post.
Stanley-Becker, Isaac (August 12, 2021). "Rand Paul discloses 16 months late that his wife bought stock in company behind covid treatment". The Washington Post. ISSN 0190-8286. Retrieved August 30, 2021.
Johnson, Carolyn Y.; Dennis, Brady (December 1, 2015). "How an $84,000 drug got its price: 'Let's hold our position … whatever the headlines'". Washington Post. Retrieved September 19, 2021.
Rowland, Christopher (May 16, 2019). "Gilead CEO insists federal government patent for HIV prevention pill Truvada is invalid". Washington Post. Retrieved September 19, 2021.
Rowland, Christopher (May 14, 2019). "Gilead is accused of cutting anti-competitive deals to extend profit on HIV drug combinations". Washington Post. Retrieved September 27, 2021.
Merle, Renae; Johnson, Carolyn Y. "The drug company that shocked the world with its prices dodged $10 billion in taxes, report says". The Washington Post. ISSN 0190-8286. Retrieved January 2, 2022.

web.archive.org

Stanton T. "Activists pounce on $1,000-a-day price for Gilead's hep C wonder drug, Sovaldi". FiercePharma. Archived from the original on February 18, 2014. Retrieved February 22, 2014.
"1996 Alumni Achievement Awards". Washington University in St. Louis. Archived from the original on August 21, 2014.
"U.S. Food And Drug Administration (FDA) Approves Atripla" (Press release). Gilead Sciences and Bristol-Myers Squibb. July 12, 2006. Archived from the original on November 15, 2008. Retrieved December 15, 2007.
"Gilead Sciences Completes Acquisition of Raylo Chemicals Inc" (Press release). Gilead Sciences. November 3, 2006. Archived from the original on January 16, 2013. Retrieved June 7, 2007.
"Parion Sciences and Gilead Sciences Sign Agreement to Advance Drug Candidates for Pulmonary Disease" (Press release). Gilead Sciences. August 15, 2007. Archived from the original on February 8, 2013. Retrieved August 15, 2007.
"Gilead Sciences to Acquire Arresto Biosciences for $225 Million; Deal Adds Pipeline Candidates for Fibrotic Diseases" (Press release). Gilead Sciences. December 20, 2010. Archived from the original on January 13, 2011. Retrieved January 15, 2011.
Perrone, Matthew. "FDA approves first pill to help prevent HIV". Today Health. NBC News. Archived from the original on July 16, 2012. Retrieved July 16, 2012.
"Gilead Sciences Announces Acquisition of Nimbus Therapeutics' Acetyl-CoA Carboxylase (ACC) Program for NASH and Other Liver Diseases | Gilead Sciences". investors.gilead.com. Archived from the original on September 23, 2021. Retrieved September 23, 2021.
"Gilead to buy Cell Design Labs for up to $567 million". reuters.com. December 7, 2017. Archived from the original on June 6, 2020.
"Gilead buys Forty Seven for $4.9 billion to bolster cancer drug pipeline". Reuters. March 2, 2020. Archived from the original on March 27, 2022.
"Gilead Completes Acquisition of Forty Seven, Inc". Gilead Sciences. Archived from the original on April 25, 2022. Retrieved April 11, 2020.
Ketaki Gokhale (December 28, 2015). "The same pill that cost $1,000 in the U.S. sold for $4 in India". Bloomberg News. Archived from the original on December 31, 2015.
"Gilead Sciences, Inc. 2019 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. Gilead Sciences. February 2020. Archived from the original (PDF) on March 13, 2022. Retrieved April 19, 2020.
"Mission & Core Values – Gilead". www.gilead.com. Archived from the original on August 11, 2022. Retrieved March 27, 2019.
Waldman R. "Gilead's HCV drug sofosbuvir approved by the FDA but accessible for how many?" (PDF). Doctors of the World. Archived from the original (PDF) on February 26, 2014. Retrieved February 22, 2014.

worldcat.org

search.worldcat.org

Fisher, Lawrence M. (June 28, 1996). "F.D.A. Approves Gilead's Drug for AIDS Patients". The New York Times. ISSN 0362-4331. Retrieved September 22, 2021.
Masho, Saba Woldemichael; Wang, Cun-Lin; Nixon, Daniel E (December 2007). "Review of tenofovir-emtricitabine". Therapeutics and Clinical Risk Management. 3 (6): 1097–1104. ISSN 1176-6336. PMC 2387297. PMID 18516268.
McNeil, Jr., Donald G. (May 9, 2019). "Gilead Will Donate Truvada to U.S. for H.I.V. Prevention". The New York Times. ISSN 0362-4331. Retrieved December 4, 2019.
McNeil, Jr., Donald G. (December 3, 2019). "200,000 Uninsured Americans to Get Free H.I.V.-Prevention Drugs". The New York Times. ISSN 0362-4331. Retrieved December 4, 2019.
Lombardo, Cara; Rockoff, Jonathan D. (September 13, 2020). "Gilead Reaches Deal to Buy Immunomedics for $21 Billion". Wall Street Journal. ISSN 0099-9660. Retrieved September 13, 2020.
Stanley-Becker, Isaac (August 12, 2021). "Rand Paul discloses 16 months late that his wife bought stock in company behind covid treatment". The Washington Post. ISSN 0190-8286. Retrieved August 30, 2021.
Sanger-Katz, Margot (August 2, 2014). "Critics Raise Concerns About Sovaldi". The New York Times. ISSN 0362-4331. Retrieved October 4, 2015.
Merle, Renae; Johnson, Carolyn Y. "The drug company that shocked the world with its prices dodged $10 billion in taxes, report says". The Washington Post. ISSN 0190-8286. Retrieved January 2, 2022.
Rizk, John G.; Forthal, Donald N.; Kalantar-Zadeh, Kamyar; Mehra, Mandeep R.; Lavie, Carl J.; Rizk, Youssef; Pfeiffer, JoAnn P.; Lewin, John C. (2021). "Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic". Drug Discovery Today. 26 (2): 593–603. doi:10.1016/j.drudis.2020.11.025. ISSN 1359-6446. PMC 7694556. PMID 33253920.

wsj.com

Silverman, Ed (December 19, 2014). "Lawsuit Alleges Price Gouging by Maker of Hepatitis Drug". Wall Street Journal. Retrieved September 19, 2021.
Silverman, Ed (September 15, 2014). "Gilead Deal to Sell Sovaldi in Poor Countries Meets Criticism". Wall Street Journal. Retrieved September 19, 2021.
"Gilead to Pay $464 Million For Triangle Pharmaceuticals". Wall Street Journal. December 4, 2002.
Lombardo, Cara; Rockoff, Jonathan D. (September 13, 2020). "Gilead Reaches Deal to Buy Immunomedics for $21 Billion". Wall Street Journal. ISSN 0099-9660. Retrieved September 13, 2020.

wustl.edu

engineering.wustl.edu

"1996 Alumni Achievement Awards". Washington University in St. Louis. Archived from the original on August 21, 2014.

yahoo.com

finance.yahoo.com

"Gilead (GILD) Collaborates with Galapagos for Filgotinib". Yahoo Finance. Yahoo/Zack's. December 18, 2015. Retrieved December 31, 2015.